{"id":20641,"date":"2023-03-22T18:27:00","date_gmt":"2023-03-22T10:27:00","guid":{"rendered":"https:\/\/flcube.com\/?p=20641"},"modified":"2025-01-06T18:31:38","modified_gmt":"2025-01-06T10:31:38","slug":"reistone-biopharmas-ivarmacitinib-shows-positive-results-in-phase-iii-quartz3-study","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=20641","title":{"rendered":"Reistone Biopharma’s Ivarmacitinib Shows Positive Results in Phase III QUARTZ3 Study"},"content":{"rendered":"\n

Reistone Biopharma Co., Ltd, incubated by Hengrui Pharmaceuticals (SHA: 600276<\/a>) with USD 100 million in 2018, has released interim data from the 16-week mark in the Phase III QUARTZ3 study. The study is assessing the efficacy of the JAK1 inhibitor ivarmacitinib in patients with moderate to severe atopic dermatitis (AD).<\/p>\n\n\n\n

Study Design and Results<\/strong>
The randomized, double-blind, placebo-controlled, global multi-center regulatory Phase III study is designed to evaluate the drug’s efficacy and safety in moderate to severe AD patients at week 52. A total of 336 subjects were enrolled. At 16 weeks, the proportion of subjects achieving IGA 0\/1 response with a decrease of \u2265 2 points from baseline (IGA response) in the 8 mg and 4 mg groups of ivarmacitinib was 42.0% and 36.3%, respectively. The proportion of subjects responding to EASI-75 was 66.1% and 54.0%, respectively, significantly higher than those in the placebo group (9.0% and 21.6%). The reduction in itching was similar in both dose groups as early as week 4 and remained consistent at week 16, with ivarmacitinib improving itching symptoms within a short period, up to 3 days after administration.<\/p>\n\n\n\n

Safety Profile<\/strong>
In terms of safety, the overall incidence of adverse events in the two dose groups was comparable to that in the placebo group. The incidence of serious adverse events and adverse events leading to discontinuation of the study drug did not increase.<\/p>\n\n\n\n

Market Potential and Context<\/strong>
Ivarmacitinib was awarded breakthrough therapy designation (BTD) status in China in January 2021 and is being prepared for market filing. Currently, there is no home-grown JAK1 inhibitor product in China. Pfizer\u2019s abrocitinib and AbbVie\u2019s upadacitinib, both oral JAK1 inhibitors, have been approved for marketing abroad and generated USD 6 million and USD 1.651 billion in global sales in 2021, respectively.-Fineline Info & Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"

Reistone Biopharma Co., Ltd, incubated by Hengrui Pharmaceuticals (SHA: 600276) with USD 100 million in…<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":false,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,11],"tags":[65,17,2586,2212,852],"class_list":["post-20641","post","type-post","status-publish","format-standard","hentry","category-company","category-drug","tag-auto-immune","tag-clinical-trial-results","tag-hengrui-pharmaceuticals","tag-reistone-biopharma","tag-sha-600276"],"yoast_head":"\nReistone Biopharma's Ivarmacitinib Shows Positive Results in Phase III QUARTZ3 Study - Insight, China's Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Reistone Biopharma Co., Ltd, incubated by Hengrui Pharmaceuticals (SHA: 600276) with USD 100 million in 2018, has released interim data from the 16-week mark in the Phase III QUARTZ3 study. The study is assessing the efficacy of the JAK1 inhibitor ivarmacitinib in patients with moderate to severe atopic dermatitis (AD).\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=20641\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Reistone Biopharma's Ivarmacitinib Shows Positive Results in Phase III QUARTZ3 Study\" \/>\n<meta property=\"og:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=20641\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China's Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2023-03-22T10:27:00+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-01-06T10:31:38+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=20641#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=20641\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Reistone Biopharma’s Ivarmacitinib Shows Positive Results in Phase III QUARTZ3 Study\",\"datePublished\":\"2023-03-22T10:27:00+00:00\",\"dateModified\":\"2025-01-06T10:31:38+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=20641\"},\"wordCount\":288,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"keywords\":[\"Auto-immune\",\"Clinical trial results\",\"Hengrui Pharmaceuticals\",\"Reistone Biopharma\",\"SHA: 600276\"],\"articleSection\":[\"Company\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=20641#respond\"]}],\"copyrightYear\":\"2023\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=20641\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=20641\",\"name\":\"Reistone Biopharma's Ivarmacitinib Shows Positive Results in Phase III QUARTZ3 Study - Insight, China's Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2023-03-22T10:27:00+00:00\",\"dateModified\":\"2025-01-06T10:31:38+00:00\",\"description\":\"Reistone Biopharma Co., Ltd, incubated by Hengrui Pharmaceuticals (SHA: 600276) with USD 100 million in 2018, has released interim data from the 16-week mark in the Phase III QUARTZ3 study. The study is assessing the efficacy of the JAK1 inhibitor ivarmacitinib in patients with moderate to severe atopic dermatitis (AD).\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=20641#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=20641\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=20641#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Reistone Biopharma’s Ivarmacitinib Shows Positive Results in Phase III QUARTZ3 Study\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Reistone Biopharma's Ivarmacitinib Shows Positive Results in Phase III QUARTZ3 Study - Insight, China's Pharmaceutical Industry","description":"Reistone Biopharma Co., Ltd, incubated by Hengrui Pharmaceuticals (SHA: 600276) with USD 100 million in 2018, has released interim data from the 16-week mark in the Phase III QUARTZ3 study. The study is assessing the efficacy of the JAK1 inhibitor ivarmacitinib in patients with moderate to severe atopic dermatitis (AD).","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=20641","og_locale":"en_US","og_type":"article","og_title":"Reistone Biopharma's Ivarmacitinib Shows Positive Results in Phase III QUARTZ3 Study","og_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","og_url":"https:\/\/flcube.com\/?p=20641","og_site_name":"Insight, China's Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2023-03-22T10:27:00+00:00","article_modified_time":"2025-01-06T10:31:38+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=20641#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=20641"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Reistone Biopharma’s Ivarmacitinib Shows Positive Results in Phase III QUARTZ3 Study","datePublished":"2023-03-22T10:27:00+00:00","dateModified":"2025-01-06T10:31:38+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=20641"},"wordCount":288,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"keywords":["Auto-immune","Clinical trial results","Hengrui Pharmaceuticals","Reistone Biopharma","SHA: 600276"],"articleSection":["Company","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=20641#respond"]}],"copyrightYear":"2023","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=20641","url":"https:\/\/flcube.com\/?p=20641","name":"Reistone Biopharma's Ivarmacitinib Shows Positive Results in Phase III QUARTZ3 Study - Insight, China's Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2023-03-22T10:27:00+00:00","dateModified":"2025-01-06T10:31:38+00:00","description":"Reistone Biopharma Co., Ltd, incubated by Hengrui Pharmaceuticals (SHA: 600276) with USD 100 million in 2018, has released interim data from the 16-week mark in the Phase III QUARTZ3 study. The study is assessing the efficacy of the JAK1 inhibitor ivarmacitinib in patients with moderate to severe atopic dermatitis (AD).","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=20641#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=20641"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=20641#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Reistone Biopharma’s Ivarmacitinib Shows Positive Results in Phase III QUARTZ3 Study"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/20641","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=20641"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/20641\/revisions"}],"predecessor-version":[{"id":20642,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/20641\/revisions\/20642"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=20641"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=20641"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=20641"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}